Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 1 of 2: GR values. - Dataset (ID:20364)

 Full screen view
Filter results: >>>>
Cell line Drug name Experimental replicate Timepoint Drug concentration Live cell count Average live cell count, DMSO control Average live cell count (time = 0) Log10(drug concentration) GR value Relative cell count (treatment versus DMSO) Cell doublings (DMSO control) Experiment name
Hs 578T XL147 1 72
3.2
 3463.8 3524.5 873.1
0.505
 0.983 0.983 2.013
Hs578T XL147 1
BT-549 PIK-93 2 72
3.2
 3525.5 4941.3 1249.6
0.505
 0.687 0.713 1.983
BT549 PIK93 0 2 72
HCC70 GDC-0980 2 72
3.2
 623.0 2310.0 722.8
0.505
 -0.085 0.270 1.676
HCC70 GDC0980 0 2 72
HCC70 Torin1 1 72
3.2
 1655.5 3250.8 1279.8
0.505
 0.211 0.509 1.345
HCC70 Torin1 0 1 72
HCC38 PI103 1 72
3.2
 1853.0 4454.3 1295.5
0.505
 0.222 0.416 1.782
HCC38 PI103 0 1 72
HCC70 Dactolisib 3 72
3.2
 1018.0 2787.8 517.3
0.505
 0.321 0.365 2.430
HCC70 BEZ235 0 3 72
Hs 578T PI103 1 72
3.2
 744.5 3645.8 873.1
0.505
 -0.074 0.204 2.062
Hs578T PI103 1
Hs 578T Sirolimus 3 72
3.2
 2472.8 4078.5 571.3
0.505
 0.676 0.606 2.836
Hs578T Rapamycin 3
Hs 578T MK2206 2 72
3.2
 2956.8 3607.8 624.7
0.505
 0.849 0.820 2.530
Hs578T MK2206 2
Hs 578T CAL-101 2 72
3.2
 2774.0 3619.3 624.7
0.505
 0.801 0.766 2.534
Hs578T CAL101 2
BT-549 PI103 2 72
3.2
 1297.5 4640.0 1249.6
0.505
 0.020 0.280 1.893
BT549 PI103 0 2 72
BT-20 WYE-125132 2 72
3.2
 831.0 3613.5 1018.6
0.505
 -0.105 0.230 1.827
BT20 WYE125132 0 2
Hs 578T GDC-0980 3 72
3.2
 838.0 4064.8 571.3
0.505
 0.145 0.206 2.831
Hs578T GDC0980 3
HCC1806 AS605240 1 72
3.2
 10191.5 11546.3 1742.8
0.505
 0.911 0.883 2.728
HCC1806 AS605240 0 1 72
Hs 578T PIK-93 1 72
3.2
 1432.3 3572.0 873.1
0.505
 0.276 0.401 2.033
Hs578T PIK93 1
HCC70 TGX221 1 72
3.2
 1925.3 3333.8 1279.8
0.505
 0.344 0.578 1.381
HCC70 TGX221 0 1 72
HCC1806 PI103 2 72
3.2
 9624.3 11113.3 1643.3
0.505
 0.898 0.866 2.758
HCC1806 PI103 0 2 72
BT-549 CAL-101 1 72
3.2
 4618.0 5381.3 1554.9
0.505
 0.836 0.858 1.791
BT549 CAL101 0 1 72
BT-549 MK2206 2 72
3.2
 6181.5 4569.8 1249.6
0.505
 1.350 1.350 1.871
BT549 MK2206 0 2 72
BT-20 Everolimus 3 72
3.2
 1503.5 3144.8 586.9
0.505
 0.475 0.478 2.422
BT20 Everolimus 0 3
BT-20 PI103 2 72
3.2
 678.8 3367.0 1018.6
0.505
 -0.210 0.202 1.725
BT20 PI103 0 2
HCC70 ZSTK474 2 72
3.2
 673.8 2409.0 722.8
0.505
 -0.040 0.280 1.737
HCC70 ZSTK474 0 2 72
Hs 578T Sirolimus 1 72
3.2
 2252.0 3525.0 873.1
0.505
 0.601 0.639 2.013
Hs578T Rapamycin 1
HCC70 Omipalisib 2 72
3.2
 92.5 2319.3 722.8
0.505
 -0.705 0.040 1.682
HCC70 GSK458 0 2 72
HCC38 PIK-93 1 72
3.2
 2970.3 4331.0 1295.5
0.505
 0.610 0.686 1.741
HCC38 PIK93 0 1 72